Molecular Partners Ag (MOLN) EBITDA (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly EBITDA of -$16799.0 for Q1 2026, up 15.64% year-on-year from -$14526.8 in Q1 2025, and up 99.98% on a QoQ basis from -$75.5 million in Q4 2025.
Molecular Partners Ag (MOLN) EBITDA (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBITDA for 7 consecutive years, with -$16799.0 the latest figure, recorded in Q1 2026.
- Quarterly EBITDA rose 15.64% year-over-year to -$16799.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$96.5 million (down 20.79% YoY) and the FY2025 annual result came in at -$72.7 million, down 4.07% from the prior year.
- EBITDA grew to -$16799.0 in Q1 2026 per MOLN's latest filing, from -$75.5 million in the prior quarter.
- Over the last five years, EBITDA for MOLN reached as high as $158.4 million in Q2 2022 and fell as low as -$75.5 million in Q4 2025.
- A 5-year average of $1.6 million and a median of -$16799.0 in 2026 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA surged 1016.85% — and 2023, when it plunged 151.62%.
- Year by year, EBITDA stood at $128.4 million in 2022, then sank by 151.62% to -$66.3 million in 2023, then rose by 6.19% to -$62.2 million in 2024, then slipped by 21.49% to -$75.5 million in 2025, then surged by 99.98% to -$16799.0 in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$16799.0, -$75.5 million, and -$14992.6 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -16,799.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,799.00 |
| Dec 31, 2025 | -75.53 Mn |
| Sep 30, 2025 | -14,992.56 |
| Jun 30, 2025 | -20.92 Mn |
| Mar 31, 2025 | -19,913.73 |
| Dec 31, 2024 | -62.16 Mn |
| Sep 30, 2024 | -21,857.22 |
| Jun 30, 2024 | -17.67 Mn |
| Mar 31, 2024 | -12,986.31 |
| Dec 31, 2023 | -66.26 Mn |
| Sep 30, 2023 | -12,963.15 |
| Jun 30, 2023 | -17.66 Mn |
| Mar 31, 2023 | -16,579.63 |
| Dec 31, 2022 | 128.36 Mn |
| Sep 30, 2022 | -13,915.50 |
| Jun 30, 2022 | 158.39 Mn |
| Mar 31, 2022 | 166,076.82 |
| Dec 31, 2021 | -68.52 Mn |
| Sep 30, 2021 | -13,548.77 |
| Jun 30, 2021 | -37.14 Mn |